



Defence Research and  
Development Canada

Recherche et développement  
pour la défense Canada



# **New advanced mass casualty breathing system for oxygen therapy:**

*Phase I*

*F. Bouak*

*D.J. Eaton*

**Defence R&D Canada**  
Technical Memorandum  
DRDC Toronto TM 2006-201  
October 2006

**Canada**



# **New advanced mass casualty breathing system for oxygen therapy**

*Phase 1*

F. Bouak  
D.J. Eaton

**Defence R&D Canada – Toronto**

Technical Memorandum

DRDC Toronto TM 2006-201

October 2006

Principal Authors

*Original signed by F. Bouak and D.J. Eaton*

---

F. Bouak and D.J. Eaton

Approved by

*Original signed by LCol B. Bain*

---

LCol B. Bain

Head, Aerospace and Undersea Medical Science Center

Approved for release by

*Original signed by K.M. Sutton*

---

K.M. Sutton

Chair, Document Review and Library Committee

In conducting the research described in this report, the investigators adhered to the policies and procedures set out in the Tri-Council Policy Statement: Ethical conduct for research involving humans, National Council on Ethics in Human Research, Ottawa, 1998 as issued jointly by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada and the Social Sciences and Humanities Research Council of Canada.

© Her Majesty the Queen as represented by the Minister of National Defence, 2006

© Sa Majesté la Reine, représentée par le ministre de la Défense nationale, 2006

## Abstract

---

This report describes the first phase of a project to develop an efficient mass casualty oxygen (O<sub>2</sub>) breathing system for O<sub>2</sub> therapy in remote areas. In this first phase, DRDC Toronto was tasked to investigate the performance of the Pulmanex<sup>®</sup> Hi-Ox<sup>®</sup> mask (Hi-Ox) at O<sub>2</sub> flow rates from 4 litres per minute (L·min<sup>-1</sup>) down to 0.5 L·min<sup>-1</sup>. Performance was evaluated with eighteen male and female volunteers between the ages of 21 and 56 years. Subjects were at rest in a seated position. The data showed that it is possible to use the Hi-Ox for O<sub>2</sub> treatment with low flow rates. The peak concentration of inhaled oxygen was 31.7±5.6% at 0.5 L·min<sup>-1</sup> and 80.3±7.8% at 4 L·min<sup>-1</sup>. To achieve a given level of O<sub>2</sub> concentration, the Hi-Ox required significantly less O<sub>2</sub> than the commonly used simple facemask. This will allow the use of portable O<sub>2</sub> concentrators to supply oxygen to the Hi-Ox, increasing the efficiency and minimizing risks.

## Résumé

---

Le présent rapport décrit la première phase d'un projet de développement d'un système efficace d'oxygénothérapie pouvant servir auprès d'un grand nombre de blessés dans les régions éloignées. Au cours de cette première phase, RDDC Toronto a été chargé d'examiner la performance du masque Pulmanex<sup>MD</sup> Hi-Ox<sup>MD</sup> (Hi-Ox) à des débits d'oxygène (O<sub>2</sub>) de 4 litres par minute (L·min<sup>-1</sup>) en diminuant jusqu'à 0,5 L·min<sup>-1</sup>. La performance a été évaluée chez dix-huit volontaires de sexe masculin et féminin âgés de 21 à 56 ans. Les sujets étaient au repos en position assise. Les données ont montré qu'il est possible d'utiliser le Hi-Ox pour l'oxygénothérapie à de faibles débits. La concentration maximale de l'oxygène inspiré était de 31,7±5,6 % à un débit de 0,5 L·min<sup>-1</sup> et de 80,3±7,8 % à un débit de 4 L·min<sup>-1</sup>. Pour obtenir une concentration donnée d'O<sub>2</sub>, le Hi-Ox requérait beaucoup moins d'O<sub>2</sub> que le masque facial simple couramment utilisé. On pourra ainsi utiliser des concentrateurs d'O<sub>2</sub> portatifs pour alimenter le Hi-Ox en oxygène, ce qui augmentera l'efficacité et réduira au minimum les risques.

This page intentionally left blank.

## Executive summary

---

### New Advanced Mass Casualty Breathing System for Oxygen Therapy: Phase 1

Bouak, F., Eaton, D. J.; DRDC Toronto TM 2006-201;  
Defence R&D Canada – Toronto; October 2006.

#### Introduction

This report describes the first phase of a project to develop an efficient mass casualty oxygen (O<sub>2</sub>) breathing system for O<sub>2</sub> therapy in remote areas. In this first phase, DRDC Toronto was tasked to investigate the inhaled O<sub>2</sub> concentration provided by the Pulmanex<sup>®</sup> Hi-Ox<sup>®</sup> mask (Hi-Ox) at O<sub>2</sub> flow rates lower than 4 litres per minute (L·min<sup>-1</sup>). The Hi-Ox mask is an open circuit continuous flow mask designed to improve gas usage efficiency, that is, low oxygen flow rates combined with high oxygen concentration. The Hi-Ox significantly exceeded the commonly used simple facemask in terms of performance and efficiency for O<sub>2</sub> flow rates higher than 4 litres per minute (L·min<sup>-1</sup>) and it was expected to outperform currently used O<sub>2</sub> masks at even low flow rates.

#### Methods

Eighteen volunteers (13 male and 5 female) between the ages of 21 and 56 years evaluated the Hi-Ox. The test procedure consisted of five breathing periods of 5 minutes each separated by 10-minute air-breaks. The oxygen flow rate was either 0.5, 1, 2, 3 or 4 L·min<sup>-1</sup> during each breathing period. Subjects were at rest breathing calmly at their own resting respiratory rate in a seated position. Measurements included inhaled and end-tidal O<sub>2</sub> and carbon dioxide (CO<sub>2</sub>) fractions, arterial blood oxygen saturation, mask pressures, exhaled gas and inhaled air volumes and inhaled gas temperature. Subjects rated their perceived breathing effort and mask discomfort.

#### Results

Data showed oxygen delivery in therapeutic ranges at low flow rates. The mean peak concentration of inhaled oxygen was 31.7±5.6% at 0.5 L·min<sup>-1</sup> and 80.3±7.8% at 4 L·min<sup>-1</sup>. To achieve a given level of O<sub>2</sub> concentration, the Hi-Ox required significantly less O<sub>2</sub> than the commonly used O<sub>2</sub> masks such as the simple facemask. For example, to achieve a peak inhaled O<sub>2</sub> concentration of 60%, the Hi-Ox required just 2 L·min<sup>-1</sup> while the simple facemask required an O<sub>2</sub> flow rate of at least 8 L·min<sup>-1</sup>. In addition, the Hi-Ox showed low levels of inhaled CO<sub>2</sub> and breathing resistance with low O<sub>2</sub> flows.

## **Significance**

It is possible to use the Hi-Ox at flow rates in the range of 0.5 to 4 L·min<sup>-1</sup>. This will allow the use of portable O<sub>2</sub> concentrators to supply O<sub>2</sub> to the Hi-Ox, increasing the efficiency and minimizing risks. Given the effectiveness of the Hi-Ox at low oxygen flows, this mask should be further investigated in the field.

# Sommaire

---

## Nouveau système d'oxygénothérapie avancé pouvant servir auprès d'un grand nombre de blessés : Phase 1

Bouak, F., Eaton, D. J.; DRDC Toronto TM 2006-201;  
R & D pour la défense Canada – Toronto; Octobre 2006.

### Introduction

Le présent rapport décrit la première phase d'un projet de mise au point d'un appareil efficace d'oxygénothérapie pouvant servir auprès d'un grand nombre de blessés dans les régions éloignées. Au cours de cette première phase, RDDC Toronto a été chargé d'examiner la performance du masque Pulmanex<sup>MD</sup> Hi-Ox<sup>MD</sup> (Hi-Ox) à des débits d'oxygène (O<sub>2</sub>) de 4 litres par minute (L·min<sup>-1</sup>). Le masque Hi-Ox est un appareil respiratoire à débit constant et à circuit ouvert conçu pour utiliser les gaz plus efficacement en combinant de faibles débits d'O<sub>2</sub> et une forte concentration d'oxygène. À des débits d'O<sub>2</sub> supérieurs à 4 litres par minute (L·min<sup>-1</sup>), la performance et l'efficacité du Hi-Ox surpassaient grandement celles du masque facial simple couramment utilisé, et on s'attendait à ce qu'il soit plus performant que les masques à O<sub>2</sub> couramment utilisés même à de faibles débits.

### Méthodologie

Dix-huit volontaires (13 hommes et 5 femmes) âgés entre 21 et 56 ans ont évalué le Hi-Ox. La procédure d'essai consistait en cinq périodes de respiration de 5 minutes, chacune séparée par des pauses de 10 minutes. Le débit d'oxygène était soit de 0,5, 1, 2, 3 ou 4 L·min<sup>-1</sup> durant chaque période de respiration. Les sujets étaient au repos en position assise et respiraient calmement à leur propre rythme respiratoire au repos. Les paramètres suivants ont été mesurés : fractions d'O<sub>2</sub> et de gaz carbonique (CO<sub>2</sub>) dans l'air inspiré et en fin d'expiration, le taux de saturation du sang artériel en oxygène, la pression dans le masque, le volume de gaz expiré et le volume d'air inspiré ainsi que la température du gaz inspiré. Les sujets ont évalué, d'après leur perception, l'effort de respiration ainsi que l'inconfort lié au masque.

### Résultats

Les données ont montré que l'appareil permettait d'administrer de l'oxygène à des niveaux thérapeutiques même à de faibles débits. Les concentrations maximales moyennes de l'oxygène inspiré étaient de 31,7±5,6 % à 0,5 L·min<sup>-1</sup> et de 80,3±7,8 % à 4 L/min. Pour obtenir une concentration donnée d'O<sub>2</sub>, le Hi-Ox requérait beaucoup moins d'O<sub>2</sub> que les masques à O<sub>2</sub> couramment utilisés tels que le masque facial simple. Par exemple, pour obtenir une concentration maximale d'O<sub>2</sub> inspiré de 60 %, le Hi-Ox n'avait besoin que d'un débit de 2 L·min<sup>-1</sup> alors que le masque facial simple nécessitait un débit d'O<sub>2</sub> d'au moins 8 L·min<sup>-1</sup>. En outre, avec le Hi-Ox à de faibles débits d'O<sub>2</sub>, on a observé de faibles niveaux de concentrations de CO<sub>2</sub> inspiré et de résistance respiratoire.

## **Importance**

Il est possible d'utiliser le Hi-Ox à des débits faibles allant de 0,5 à 4 L·min<sup>-1</sup>. On pourra ainsi utiliser des concentrateurs d'O<sub>2</sub> portatifs pour alimenter le Hi-Ox en O<sub>2</sub>, ce qui accroîtra l'efficacité et réduira au minimum les risques. Compte tenu de l'efficacité du masque Hi-Ox à de faibles débits d'oxygène, ce masque devrait être évalué plus à fond sur le terrain.

# Table of contents

---

Abstract .....	i
Résumé .....	i
Executive summary .....	iii
Sommaire.....	v
Table of contents .....	vii
List of figures .....	viii
List of tables .....	viii
Acknowledgements .....	ix
1. Introduction.....	1
2. Methods and Materials.....	3
2.1 Subjects .....	3
2.2 Experimental set-up and data acquisition .....	3
2.3 Procedure.....	5
2.4 Statistical analysis .....	6
3. Results.....	7
3.1 Arterial blood oxygen saturation, $SaO_2$ .....	7
3.2 Inhaled oxygen fraction, $f_I O_2$ .....	8
3.3 Inhaled and end-tidal carbon dioxide fractions, $f_I CO_2$ and $f_{ET} CO_2$ .....	9
3.4 Peak inhale and exhale pressures, $P_{inh}$ and $P_{exh}$ .....	10
3.5 Subjective rating .....	11
4. Discussion and Conclusions .....	12
5. Recommendations.....	14
References .....	15
Annex A Experimental Data .....	17
Annex B Termination Criteria.....	19
List of symbols/abbreviations/acronyms/initialisms .....	20
Distribution List .....	21

## List of figures

---

Figure 1: The Pulmanex <sup>®</sup> Hi-Ox <sup>®</sup> mask.....	1
Figure 2: Instrumented mask detail.....	4
Figure 3: Mean arterial oxygen saturation. (*) p<0.05, 0.5 L·min <sup>-1</sup> compared to 3 and 4 L·min <sup>-1</sup> .....	7
Figure 4: Mean inhaled oxygen fractions (peak values and values from alveolar equation) .....	8
Figure 5: Mean inhaled and end-tidal carbon dioxide fractions .....	9
Figure 6: Mean peak inhale and exhale pressures .....	10
Figure 7: Mask discomfort (MD) and breathing effort (BE) ratings obtained from a 10-point scale.....	11

## List of tables

---

Table 1. Subjects Characteristics.....	3
Table 2. Literature comparison of inhaled O <sub>2</sub> fractions (x 100).....	12

## Acknowledgements

---

The investigation was funded by the Canadian Forces Health Services Group Headquarters (CF H Svc Gp HQ), in collaboration with Defence R&D Canada – Toronto. The authors would like to acknowledge the sustained dedication of Mr. David Eastman who provided operational support and undertook a wide variety of tasks before, during and after the experiment. These include installing and preparing the experimental set-up, overseeing subject recruitment, organizing medical screening and monitoring the experiment. The investigators would like to thank Mr. Robert MacLean for his valuable help and for installing and programming the data acquisition system.

This page intentionally left blank.

# 1. Introduction

---

The Pulmanex<sup>®</sup> Hi-Ox<sup>®</sup> Mask (Hi-Ox) (Figure 1), formerly the Hi-Ox<sup>80</sup>, is a commercial product manufactured by VIASYS MedSystems. It is an open circuit continuous flow mask designed to improve gas usage efficiency, that is, low supply oxygen flow rates ( $Q_{O_2}$ ) combined with high oxygen ( $O_2$ ) concentration. The Hi-Ox is also designed to prevent excess carbon dioxide ( $CO_2$ ) elimination so that respiratory centre excitation produced by  $CO_2$  chemoreceptors remains stable.




Figure 1: The Pulmanex<sup>®</sup> Hi-Ox<sup>®</sup> mask.

Bouak and Eaton [1] reported that the Hi-Ox significantly exceeded the commonly used simple facemask in terms of performance and efficiency for  $O_2$  flow rates between 4 and 9 litres per minute ( $L \cdot \text{min}^{-1}$ )<sup>1</sup>. Basically, the Hi-Ox delivered more  $O_2$  at lower flow rates. For example, the peak inhaled  $O_2$  fraction ( $f_i O_2$ ) was above 91% for flow rates greater than  $7 L \cdot \text{min}^{-1}$  and was 80% at  $4 L \cdot \text{min}^{-1}$  while the highest  $f_i O_2$  delivered by the simple facemask was 60% at  $9 L \cdot \text{min}^{-1}$ .

Given that the  $O_2$  concentrations provided by currently available open-circuit masks such as the simple facemask [2] and the Venturi mask [2] are adequate in many situations, that is, low to moderate  $O_2$  concentrations, it might be possible to use the Hi-Ox for achieving these  $O_2$  levels with lower  $Q_{O_2}$ . Taking into account that weight, volume and risk restrictions dictate the amount of  $O_2$  available to the patient in the field, the use of a low flow rate mask such as the Hi-Ox

---

<sup>1</sup> All flow rates are referenced to  $0^\circ\text{C}$  and 101.3 kPa, dry gas i.e. standard temperature and pressure, dry (STPD) unless indicated.

should decrease O<sub>2</sub> requirement for treatment in remote areas. DRDC Toronto proposed that the Hi-Ox could form the basis of an oxygen therapy system that would be supplied by miniature oxygen concentrators now being developed. This combination would eliminate the risk of transporting and using compressed oxygen in the field. Since the current literature does not address the delivery of O<sub>2</sub> by the Hi-Ox at low flows, this study examines the flexibility of using the Hi-Ox at flow rates in the range of 0.5 to 4 L·min<sup>-1</sup>.

## 2. Methods and Materials

---

### 2.1 Subjects

A total of eighteen military and civilian subjects, thirteen male and five female, between the ages of 21 and 56, volunteered to participate in this study. They were recruited from DRDC Toronto staff. Prior to conducting the experiments, all subject candidates underwent a medical screening by a physician to determine respiratory symptoms and eligibility. The DRDC Human Research Ethics Committee (HREC) approved the experimental protocol [3]. All subjects gave their written consent after being informed of the details, discomforts and risks associated with the experimental protocol. Remuneration for participation complied with guidelines established by DRDC Toronto. No subject withdrew from the study. Table 1 summarizes their physical characteristics. Table A1 in Annex A lists individual subject characteristics.

*Table 1. Subjects Characteristics.*

	Mean $\pm$ SD	Range
<b>Age (yr)</b>	38.17 $\pm$ 9.31	21 – 56
<b>Weight (kg)</b>	79.53 $\pm$ 17.01	52 – 102.9
<b>Height (m)</b>	1.73 $\pm$ 0.09	1.57 – 1.83

### 2.2 Experimental set-up and data acquisition

Aviator's breathing oxygen [4] was provided from a K-cylinder (244 ft<sup>3</sup> STPD) using a high purity oxygen regulator (Matheson Gas Products, Model 3104C). The supply oxygen flow rates were adjusted using a computer-controlled mass flow controller (Brooks 5850 series, 0-10 L·min<sup>-1</sup>). A chain-compensated gasometer (Warren E. Collins, 120 L) was used to calibrate the flow controller.

The oronasal mask was instrumented to measure O<sub>2</sub> and CO<sub>2</sub> fractions, temperature and pressure (Figure 2).

A gas sample line (Intramedic polyethylene tubing by Clay Adams, Model PE-60, 0.76 mm I.D. x 1.22 mm O.D. x 1 m long) and the mask thermistor (Yellow Spring Instrument, Model 44004) were inserted into the facemask about two centimetres from the subject's mouth and nose. Mask gas was constantly sampled at a flow rate of 30 millilitres per minute (mL·min<sup>-1</sup>). The sample line was connected to the mass spectrometer (Hiden HPR20) via a heated capillary line of about 1.9 m long. For the flow rate and the sample line length used in this experiment, the sample line delay was about 6 sec.




Figure 2: Instrumented mask detail.

Before each trial, the mass spectrometer was calibrated using two calibration gases (certification tolerance:  $\pm 0.02$  mole %), one with 100%  $O_2$  and the other being a mixture of 5%  $CO_2$ , 75%  $O_2$  and 20% nitrogen ( $N_2$ ).

A second sample line penetrated the left side of the mask (Figure 2) and was dead-ended to a pressure transducer (Validyne DP-15,  $\pm 0.5$  psi diaphragm) for measuring instantaneous mask pressure.

Exhaled gas passed through a turbine volume transducer (Ventilation Measurement Modules by Interface Associates), incorporated in the exhale side of the Hi-Ox (Figure 2), to compute respiratory minute volume,  $\dot{V}_E$ , and inhaled atmospheric air through the exhale port of the mask.

Arterial blood oxygen saturation ( $SaO_2$ ) was measured with a pulse oximeter (OXI by Radiometers Copenhagen) connected to the index or the middle finger of the subject's right hand. The measurements were taken before and during oxygen breathing for each  $O_2$  flow rate.

Data from the instruments were continuously measured at a sampling frequency of 50 Hz. All lines from the instruments were connected to a data acquisition (DAQ) card (National Instruments, PCI-6052E) via a terminal block (National Instruments, TBX-68). The DAQ card was installed into a desktop computer running MS Windows 2000. All experimental data were stored on the hard drive of the computer for further computation and statistical analysis. The DAQ card and computer were controlled using custom-written software in LabVIEW™ (National Instruments).

Custom-written analysis software (written using LabVIEW™) was used to derive variables from the measured values. Instantaneous O<sub>2</sub> and CO<sub>2</sub> fractions ( $f_mO_2$ ,  $f_mCO_2$ ) were used to compute inhaled and end-tidal gas fractions for each breath. Inhaled CO<sub>2</sub> fraction ( $f_I CO_2$ ) was taken at the time of the lowest  $f_mCO_2$  in each breath while end tidal values of both O<sub>2</sub> and CO<sub>2</sub> ( $f_{ET}CO_2$  and  $f_{ET}O_2$ ) were taken at the time of the highest  $f_mCO_2$  in each breath. Peak  $f_I O_2$  were determined from the maximum values of  $f_mO_2$ . For comparison purposes only, inhaled O<sub>2</sub> fraction ( $f_I O_2$ ) was also determined from  $f_{ET}CO_2$  and  $f_{ET}O_2$  through the alveolar gas equation [5]:

$$f_A O_2 = f_I O_2 - (f_A CO_2 / RQ) \times (1 - f_I O_2 (1 - RQ))$$

The alveolar fraction of CO<sub>2</sub> ( $f_A CO_2$ ) was assumed equal to  $f_{ET}CO_2$  and the respiratory quotient ( $RQ$ ) was assumed to be 0.8.

Minute-averaged values were then calculated for each computed fraction. Finally, a mean value was calculated for the last three minutes of each breathing period for analysis.

Mask thermistor and pressure data were used for determining end-inhalation and end-tidal temperatures and peak inhale and exhale pressures ( $P_{Ins}$  and  $P_{Exp}$ ), respectively.

Subjects rated their perceived level for breathing effort ( $BE$ ) and mask discomfort ( $MD$ ). Rating tests were based on a 0 – 10 subjective scale [6].

## 2.3 Procedure

Baseline anthropometric measurements (weight and height) were collected for each subject (see Table A1, Annex A).

All tests were carried out at DRDC Toronto and subjects went through the following procedures:

- Subjects were first briefed on the test procedures, the use of the breathing unit to be tested and the psychophysical scales used to assess the breathing effort and mask discomfort.
- An attendant instructed the subject in the proper use and fit of the Hi-Ox. The subject's arterial blood oxygen saturation was measured before going on O<sub>2</sub>. Then, the subject donned the Hi-Ox and was asked to breathe calmly at their own resting respiratory rate from the mask.
- The experiment was broken into five periods of 5 min each separated by 10 min air-breaks. Subjects rated breathing effort and mask discomfort at the end of each 5-min period. During these air-breaks, subjects took off their masks and breathed air. The O<sub>2</sub> flow rate, either 0.5, 1, 2, 3, 4 L·min<sup>-1</sup>, was selected in random order.

Any 5-minute period was halted when one of the criteria listed in Annex B were met.

## **2.4 Statistical analysis**

Subject's Oxygen blood saturation, O<sub>2</sub> and CO<sub>2</sub> levels, mask pressures, and subjective rating for breathing effort and mask discomfort were analyzed using multi-factor, repeated measures analysis of variance to determine any significant differences in the dependent variables between the O<sub>2</sub> flow rates (breathing periods).

### 3. Results

Eighteen subjects completed the evaluation of the Hi-Ox at low  $Q_{O_2}$ . Mean values of  $SaO_2$ ,  $f_I O_2$ ,  $f_I CO_2$ ,  $f_{ET} CO_2$  and peak inhale and exhale pressures, averaged across all 18 subjects, are shown in Figures 3 to 6 respectively. In all figures, error bars are standard deviations.

#### 3.1 Arterial blood oxygen saturation, $SaO_2$

Figure 3 shows that the Hi-Ox significantly increased  $SaO_2$  at each  $O_2$  flow rate. For example, at  $2 \text{ L}\cdot\text{min}^{-1}$ ,  $SaO_2$  increased from 95.1% without a mask to 98.3% with the Hi-Ox. Overall, the mean  $SaO_2$  increased gradually with the increase of  $Q_{O_2}$ . Only the differences between 0.5 and 3  $\text{L}\cdot\text{min}^{-1}$  and 0.5 and 4  $\text{L}\cdot\text{min}^{-1}$  were significant ( $p < 0.05$ ).




Figure 3: Mean arterial oxygen saturation. (\*)  $p < 0.05$ ,  $0.5 \text{ L}\cdot\text{min}^{-1}$  compared to 3 and 4  $\text{L}\cdot\text{min}^{-1}$ .

### 3.2 Inhaled oxygen fraction, $f_I O_2$

Inhaled  $O_2$  fraction significantly increased ( $p < 0.0001$ ) with the increase of  $Q_{O_2}$  (Figure 4). Peak  $f_I O_2$  varied from  $31.7 \pm 5.3\%$  at a  $Q_{O_2}$  of  $0.5 \text{ L}\cdot\text{min}^{-1}$  to  $80.1 \pm 7.7\%$  at  $4 \text{ L}\cdot\text{min}^{-1}$ , while mean  $f_I O_2$  from the alveolar fraction ranged from  $27.5 \pm 1.8\%$  at  $0.5 \text{ L}\cdot\text{min}^{-1}$  to  $60.1 \pm 7.9\%$  at  $4 \text{ L}\cdot\text{min}^{-1}$ .




Figure 4: Mean inhaled oxygen fractions (peak values and values from alveolar equation)

### 3.3 Inhaled and end-tidal carbon dioxide fractions, $f_i\text{CO}_2$ and $f_{ET}\text{CO}_2$

Figure 5 shows mean  $f_i\text{CO}_2$  and  $f_{ET}\text{CO}_2$  at each  $Q_{O_2}$ . On average, the Hi-Ox was able to maintain low  $f_i\text{CO}_2$  levels ( $< 0.5\%$ ) and  $f_{ET}\text{CO}_2$  nearly constant (around 5%). Oxygen flow rate had no significant effect on both  $f_i\text{CO}_2$  and  $f_{ET}\text{CO}_2$ .




Figure 5: Mean inhaled and end-tidal carbon dioxide fractions

### 3.4 Peak inhale and exhale pressures, $P_{inh}$ and $P_{exh}$

Whereas,  $Q_{O_2}$  had no significant effect on either the peak inhale or exhale pressures, these two pressures were slightly higher at 0.5 and 1  $L \cdot min^{-1}$  (Figure 6). On average, the highest peak inhale pressure was less than 2  $cm H_2O$ .




Figure 6: Mean peak inhale and exhale pressures

### 3.5 Subjective rating

Overall, the Hi-Ox rated, as shown in Figure 7, below “light” (<2 on a 10-point scale) for both mask discomfort, MD, and breathing effort, BE. Whereas, there was no significant difference between O<sub>2</sub> flows, both MD and BE were slightly lower at 3 and 4 L·min<sup>-1</sup>.

Subjects were also asked to give overall comments on the breathing unit or any other perceived discomforts (e.g., dryness, headache). The majority of the subjects complained about the lack of robustness of the two elastic straps. Several subjects indicated that O<sub>2</sub> leaked around the nose. Other subjects mentioned that the oronasal mask was slightly small.




Figure 7: Mask discomfort (MD) and breathing effort (BE) ratings obtained from a 10-point scale.

## 4. Discussion and Conclusions

A total of 18 subjects used a Hi-Ox to evaluate its performance in terms of inhaled O<sub>2</sub> and CO<sub>2</sub> fractions and breathing resistance at low oxygen flows (i.e., 0.5, 1, 2, 3 and 4 L·min<sup>-1</sup>). At an O<sub>2</sub> flow rate of 4 L·min<sup>-1</sup>, the Hi-Ox delivered a peak O<sub>2</sub> concentration of 80.3%, which is in agreement with the value obtained in a previous study [1] with the same conditions ( $t=0.368$ ,  $p=0.72$ ) (see Table 2).

The oxygen level prescribed by a physician depends on the clinical condition of the patient. The present data showed that the Hi-Ox can cover clinical conditions that require, for example, an O<sub>2</sub> level of 60% given a supply O<sub>2</sub> flow rates of only 2 L·min<sup>-1</sup>. For a patient at rest, this is significantly less O<sub>2</sub> than the commonly used O<sub>2</sub> breathing units such as the simple facemask which would require 8 L·min<sup>-1</sup> to achieve the same O<sub>2</sub> level [1]. Even at 0.5 and 1 L·min<sup>-1</sup> the Hi-Ox delivers clinically useful O<sub>2</sub> concentrations (Table 2).

Table 2. Literature comparison of inhaled O<sub>2</sub> fractions (x 100).

O <sub>2</sub> flow L·min <sup>-1</sup>	Peak f <sub>i</sub> O <sub>2</sub>			f <sub>i</sub> O <sub>2</sub> from the alveolar equation [5]	
	Current	Hi-Ox [1]	Simple facemask [1]	Current	Hi-Ox [7]
0.5	31.7±5.6			27.5±1.8	
1	44.1±8.2			33.4±3.4	
2	60.2±8.9			42.8±5.6	50.0±7.0
3	68.6±8.2			52.9±8.2	
4	80.3±7.8	79.60±6.2	50.13±6.7	60.0±7.9	73.0±6.0

Note: Mean±SD

With subjects breathing at their resting respiratory rate, Slessarev et al. [7] showed that the Hi-Ox, at 4 L·min<sup>-1</sup>, achieved higher O<sub>2</sub> concentration than the non-rebreathing mask (NRM) at 8 L·min<sup>-1</sup>. Table 2 compares  $f_iO_2$  obtained in this study to Slessarev's data<sup>2</sup>. It appears that the latter are about 17 to 20% greater than the present data. This is mainly due to mask leaks encountered in the present study. While adhesive tape was used to ensure mask seal in Slessarev's investigation, the only attempt taken to seal mask leaks in this study was to fit the mask tight on the subject's face by using the mask's two elastic straps and the metal strip (see Figure 1). In addition, because the Hi-Ox was available in only one size<sup>3</sup> (adult size), mask leaks were worse when subjects had a small face, further diluting inhaled gas.

<sup>2</sup> Only  $f_iO_2$  computed from the alveolar equation were compared.

<sup>3</sup> A paediatric Hi-Ox is now available.

The present study showed that the Hi-Ox significantly increased the blood O<sub>2</sub> saturation at each O<sub>2</sub> flow. With a low level of inhaled carbon dioxide and breathing resistance, it is possible to use the Hi-Ox at flow rates in the range of 0.5 to 4 L·min<sup>-1</sup>, decreasing O<sub>2</sub> requirement for treatment in remote areas and allowing the use of portable O<sub>2</sub> concentrators. This would increase efficiency and safety by replacing the need for bulky, dangerous compressed oxygen cylinders or chemical generators.

Fisher [8] reported that the Hi-Ox can be modified to deliver high O<sub>2</sub> concentrations with lower supply O<sub>2</sub> flow rates than the currently available Hi-Ox. It was claimed that O<sub>2</sub> concentration of the inhaled gas would increase from 80% to 100% at 4 L·min<sup>-1</sup>. For this, a special rebreathing bag would be connected to the exhale port of the Hi-Ox's manifold (see Figure 1) while the second end would be open to the atmosphere. If Fisher's claims are valid then the modified version of the Hi-Ox would increase the duration of O<sub>2</sub> supply, however, it is possible that this added bag may have some effects on the CO<sub>2</sub> level of inhaled gas. Future experiments should investigate the effectiveness of the Hi-Ox with the exhale side rebreathing bag.

## 5. Recommendations

---

Given the effectiveness of the Hi-Ox at low oxygen flows ( $\leq 4 \text{ L}\cdot\text{min}^{-1}$ ), it is recommended to:

- a. field test the Hi-Ox to assess its ruggedness;
- b. evaluate the Hi-Ox using an  $\text{O}_2$  concentrator;
- c. assess the effectiveness of the Hi-Ox with the exhale side rebreathing bag; and
- d. investigate the effect of cold temperatures on the one-way valves of the Hi-Ox.

## References

---

- [1] Bouak, F. and Eaton, D. J. (2005). Possibilities for mass casualty oxygen systems in search and rescue missions. Part 1: The VIASYS Hi-Ox<sup>80™</sup> mask. (DRDC Toronto TR 2005-207). Defence R&D Canada – Toronto.
- [2] Bouak, F. and Eaton, D. J. (2004). Oxygen therapy. (DRDC Toronto TM 2004-112). Defence R&D Canada – Toronto.
- [3] Bouak, F. and Eaton, D. J. Performance of oxygen breathing systems for search missions. DRDC Human Research Ethics Committee Protocol #L-472, Amendment #2. Defence R&D Canada – Toronto. 06 Dec. 2005.
- [4] Canadian Forces. (1987). *Oxygen Aviator's Breathing, Liquid and Gaseous*. CF standard D-22-03-003/SF-000 1987-10-27 Table 1, Department of National Defence, Canada.
- [5] Siggaard-Andersen, O., Wimberly, P. D., Fogh-Andersen, N. and Gothgen, I. H. (1988). Measured and derived quantities with modern pH and blood gas equipment: calculation algorithms with 54 equations. *The Scandinavian J of Clinical & Laboratory Investigation*, 48, Suppl. 189, 7-15.
- [6] Eaton, D. J. (1988). Estimating motor performance decrements using ratings of perceived discomfort. M.Sc. Thesis, University of Guelph, Guelph, Ontario, Canada.
- [7] Slessarev, M., Somogyi, R., Preiss, D., Vesely, A., Sasano, H. and Fisher, J. A. (2006). Efficiency of oxygen administration: Sequential gas delivery versus “flow into a cone” methods. *Crit. Care Med.*, 34(3), 829-834.
- [8] Fisher, J. A. (2004). Private communication. University Health Network. Toronto.

This page intentionally left blank.

## Annex A Experimental Data

---

*Table A1. Physical Description of the Subjects*

ID	Sex	Age <i>year</i>	Weight <i>kg</i>	Height <i>cm</i>
S01	Female	41	70.5	166
S02	Male	42	70.3	170
S03	Male	53	70.3	174
S04	Female	22	59.0	174
S05	Male	41	91.6	183
S06	Male	33	88.5	183
S07	Female	41	55.8	157
S08	Male	41	108.9	183
S09	Male	28	101.0	183
S10	Male	44	72.6	174
S11	Female	28	63.5	157
S12	Male	39	81.6	173
S13	Male	56	99	183
S14	Male	44	81.6	168
S15	Male	42	90.7	171
S16	Male	35	72.6	173
S17	Male	36	102.1	183
S18	Female	21	52.0	161
Mean		38.17	79.5	173
SD		9.31	17.0	9

This page intentionally left blank.

## Annex B Termination Criteria

---

Experiments were stopped when any of the following criteria were reached:

- Subject request associated with fatigue, discomfort or any other reason.
- Total pure O<sub>2</sub> breathing duration reaches 30 minutes.
- Loss of O<sub>2</sub> supply.
- Arterial O<sub>2</sub> blood saturation goes below 92%.
- Inhaled O<sub>2</sub> fraction goes below 21%
- Inhaled CO<sub>2</sub> fraction exceeds 0.5% by volume.
- Loss of room ventilation.
- Excessive breathing resistance (peak inhale or exhale pressures no greater than  $\pm 10$  cm H<sub>2</sub>O over 5 min).

## List of symbols/abbreviations/acronyms/initialisms

---

<i>BE</i>	Breathing effort
CF H Svc Gp HQ	Canadian Forces Health Services Group Headquarters
DND	Department of National Defence
DRDC	Defence R&D Canada
$f_A CO_2$	Alveolar carbon dioxide fraction
$f_{ET} CO_2$	End tidal carbon dioxide fraction
$f_{ET} O_2$	End tidal oxygen fraction
$f_I CO_2$	Inhaled carbon dioxide fraction
$f_I O_2$	Inhaled oxygen fraction
ft <sup>3</sup>	Cubic foot
Hi-Ox	Pulmanex <sup>®</sup> Hi-Ox <sup>®</sup> mask
L·min <sup>-1</sup>	Litres per minute
<i>MD</i>	Mask discomfort
NRM	Non-rebreathing mask
O <sub>2</sub>	Oxygen
OPI	Office of Primary Interest
$P_{exh}$	Peak exhale mask pressure (cm H <sub>2</sub> O)
$P_{inh}$	Peak inhale mask pressure (cm H <sub>2</sub> O)
psi or psig	Pound square inch or pound square inch gage
Q <sub>O<sub>2</sub></sub>	Supply oxygen flow rate
<i>RQ</i>	Respiratory quotient
R&D	Research & Development
$SaO_2$	Arterial blood oxygen saturation
SD	Standard deviation

## **Distribution list**

---

Document No.: DRDC Toronto TM 2006-201

### LIST PART 1: Internal Distribution by Centre:

- 7 – F. Bouak (DRDC Toronto/IRPR), Author
- 1 – D. Eaton (DRDC Toronto/AUMS/SEG), Author
- 1 – D. Eastman (DRDC Toronto/AUMS/SEG)
- 1 – R. MacLean (DRDC Toronto/AUMS/SEG)

---

TOTAL LIST PART 1: 10

### LIST PART 2: External Distribution by DRDKIM

---

TOTAL LIST PART 2:

**TOTAL COPIES REQUIRED: 10**

This page intentionally left blank.

**DOCUMENT CONTROL DATA**

(Security classification of title, body of abstract and indexing annotation must be entered when the overall document is classified)

1. ORIGINATOR (The name and address of the organization preparing the document. Organizations for whom the document was prepared, e.g. Centre sponsoring a contractor's report, or tasking agency, are entered in section 8.)		2. SECURITY CLASSIFICATION (Overall security classification of the document including special warning terms if applicable.)	
DRDC Toronto		UNCLASSIFIED	
3. TITLE (The complete document title as indicated on the title page. Its classification should be indicated by the appropriate abbreviation (S, C, R or U) in parentheses after the title.)			
New Advanced Mass Casualty Breathing System for Oxygen Therapy: Phase 1			
4. AUTHORS (last name, followed by initials – ranks, titles, etc. not to be used)			
Bouak, F., Eaton, D. J.			
5. DATE OF PUBLICATION (Month and year of publication of document.)	6a. NO. OF PAGES (Total containing information, including Annexes, Appendices, etc.)	6b. NO. OF REFS (Total cited in document.)	
October 2006	40	8	
7. DESCRIPTIVE NOTES (The category of the document, e.g. technical report, technical note or memorandum. If appropriate, enter the type of report, e.g. interim, progress, summary, annual or final. Give the inclusive dates when a specific reporting period is covered.)			
Technical Memorandum			
8. SPONSORING ACTIVITY (The name of the department project office or laboratory sponsoring the research and development – include address.)			
Canadian Forces Health Services Group Headquarters (CF H Svc Gp HQ), Ottawa, ON Canada Ottawa, ON Canada			
9a. PROJECT OR GRANT NO. (If appropriate, the applicable research and development project or grant number under which the document was written. Please specify whether project or grant.)	9b. CONTRACT NO. (If appropriate, the applicable number under which the document was written.)		
20cc38			
10a. ORIGINATOR'S DOCUMENT NUMBER (The official document number by which the document is identified by the originating activity. This number must be unique to this document.)	10b. OTHER DOCUMENT NO(s). (Any other numbers which may be assigned this document either by the originator or by the sponsor.)		
DRDC Toronto TM 2006-201			
11. DOCUMENT AVAILABILITY (Any limitations on further dissemination of the document, other than those imposed by security classification.)			
<input checked="" type="checkbox"/> Unlimited distribution <input type="checkbox"/> Defence departments and defence contractors; further distribution only as approved <input type="checkbox"/> Defence departments and Canadian defence contractors; further distribution only as approved <input type="checkbox"/> Government departments and agencies; further distribution only as approved <input type="checkbox"/> Defence departments; further distribution only as approved <input type="checkbox"/> Other (please specify):			
12. DOCUMENT ANNOUNCEMENT (Any limitation to the bibliographic announcement of this document. This will normally correspond to the Document Availability (11). However, where further distribution (beyond the audience specified in (11) is possible, a wider announcement audience may be selected.)			
Unlimited announcement			

13. **ABSTRACT** (A brief and factual summary of the document. It may also appear elsewhere in the body of the document itself. It is highly desirable that the abstract of classified documents be unclassified. Each paragraph of the abstract shall begin with an indication of the security classification of the information in the paragraph (unless the document itself is unclassified) represented as (S), (C), (R), or (U). It is not necessary to include here abstracts in both official languages unless the text is bilingual.)

This report describes the first phase of a project to develop an efficient mass casualty oxygen (O<sub>2</sub>) breathing system for O<sub>2</sub> therapy in remote areas. In this first phase, DRDC Toronto was tasked to investigate the performance of the Pulmanex<sup>®</sup> Hi-Ox<sup>®</sup> mask (Hi-Ox) at O<sub>2</sub> flow rates from 4 litres per minute (L·min<sup>-1</sup>) down to 0.5 L·min<sup>-1</sup>. Performance was evaluated with eighteen male and female volunteers between the ages of 21 and 56 years. Subjects were at rest in a seated position. The data showed that it is possible to use the Hi-Ox for O<sub>2</sub> treatment with low flow rates. The peak concentration of inhaled oxygen was 31.7±5.6% at 0.5 L·min<sup>-1</sup> and 80.3±7.8% at 4 L·min<sup>-1</sup>. To achieve a given level of O<sub>2</sub> concentration, the Hi-Ox required significantly less O<sub>2</sub> than the commonly used simple facemask. This will allow the use of portable O<sub>2</sub> concentrators to supply oxygen to the Hi-Ox, increasing the efficiency and minimizing risks.

Le présent rapport décrit la première phase d'un projet de développement d'un système efficace d'oxygénothérapie pouvant servir auprès d'un grand nombre de blessés dans les régions éloignées. Au cours de cette première phase, RDDC Toronto a été chargé d'examiner la performance du masque Pulmanex<sup>MD</sup> Hi-Ox<sup>MD</sup> (Hi-Ox) à des débits d'oxygène (O<sub>2</sub>) de 4 litres par minute (L·min<sup>-1</sup>) en diminuant jusqu'à 0,5 L·min<sup>-1</sup>. La performance a été évaluée chez dix-huit volontaires de sexe masculin et féminin âgés de 21 à 56 ans. Les sujets étaient au repos en position assise. Les données ont montré qu'il est possible d'utiliser le Hi-Ox pour l'oxygénothérapie à de faibles débits. La concentration maximale de l'oxygène inspiré était de 31,7±5,6 % à un débit de 0,5 L·min<sup>-1</sup> et de 80,3±7,8 % à un débit de 4 L·min<sup>-1</sup>. Pour obtenir une concentration donnée d'O<sub>2</sub>, le Hi-Ox requérait beaucoup moins d'O<sub>2</sub> que le masque facial simple couramment utilisé. On pourra ainsi utiliser des concentrateurs d'O<sub>2</sub> portatifs pour alimenter le Hi-Ox en oxygène, ce qui augmentera l'efficacité et réduira au minimum les risques.

14. **KEYWORDS, DESCRIPTORS or IDENTIFIERS** (Technically meaningful terms or short phrases that characterize a document and could be helpful in cataloguing the document. They should be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code name, geographic location may also be included. If possible keywords should be selected from a published thesaurus, e.g. Thesaurus of Engineering and Scientific Terms (TEST) and that thesaurus identified. If it is not possible to select indexing terms which are Unclassified, the classification of each should be indicated as with the title.)

Pulmanex<sup>®</sup> Hi-Ox<sup>®</sup> mask, VIASYS Hi-Ox80; First-aid oxygen, O2 concentrator



## **Defence R&D Canada**

Canada's Leader in Defence  
and National Security  
Science and Technology

## **R & D pour la défense Canada**

Chef de file au Canada en matière  
de science et de technologie pour  
la défense et la sécurité nationale



[www.drdc-rddc.gc.ca](http://www.drdc-rddc.gc.ca)

